In LUAD, USP7 suppresses c-Myc degradation to promote EMT and cisplatin resistance in vitro271, and USP22 stabilizes c-Myc and ALDH1A3 to facilitate EMT and resistance in TNBC and lung cancer in vitro and in vivo272, 273. The gene discussed is MYC; the disease is lung carcinoma.